New scan spots hidden organ damage before symptoms start
NCT ID NCT07624760
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole-body scan. The goal is to see if this method can identify amyloid buildup early and without the need for tissue biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-Florbetaben (Neuraceq)
- What this could lead to
- If successful, this imaging method could allow earlier, non-invasive detection of organ damage in people with blood disorders, potentially improving treatment timing.
- What could go wrong
- This is a small, early observational study. The imaging agent may not reliably detect all amyloid deposits, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Zurich
Zurich, Canton of Zurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact